The accessory gene vif is present in genomes of all known lentiviruses, with the exception of equine infective anemia virus, and is a potential target for virus attenuation and restriction. Vif has been shown to be required for efficient viral replication both in vitro and in vivo for multiple animal lentiviruses (Desrosiers et al., 1998; Gabuzda et al., 1992; Gupta et al., 2007; Harmache et al., 1996; Inoshima et al., 1996; Kristbjornsdottir et al., 2004; Lockridge et al., 1999; Paul et al., 2007; Shacklett & Luciw, 1994) . Vif protein expressed by primate lentiviruses, including human immunodeficiency virus and simian immunodeficiency virus (SIV), facilitate viral infectivity by targeting cellular cytidine deaminases of the APOBEC3 family, including APOBEC3G, for proteosomal degradation and thereby inhibit virion incorporation of these antiviral cellular proteins (Cullen, 2006; Sheehy et al., 2002) . An association between feline immunodeficiency virus (FIV) Vif and a feline analogue for APOBEC3G has not been characterized at this time. However, a recent report described interactions between a feline cytidine deaminase (fe3) most related to human APOBEC3F and the feline spumavirusencoded bet gene product (Lochelt et al., 2005) . A second report revealed that replication of a non-domestic feline lentivirus (FIV-OMA) in a cell line characterized by stable expression of FIV-OMA Vif, resulted in a reduction of Gto-A mutation rates for viral genomes (Paul et al., 2007) . These findings suggest that FIV Vif interacts with a feline cytidine deaminase similar to those described for primate lentivirus Vif proteins.
Although vif deletion mutants of multiple lentiviruses have proven severely attenuated after experimental infection of adult and adolescent animals, effects of vif mutation on virus replication in the neonatal host have not been reported. Infection of neonatal hosts with wild-type primate lentiviruses or FIV resulted in higher virus loads and a more rapid disease progression compared with adult infections and revealed that potential pathogenicity of a lentivirus is also complicated by the age of the host (Chakraborty, 2005; George et al., 1993; Marthas et al., 1995; Veazey et al., 2003) . Furthermore, a nef-deleted SIV mutant, previously shown to be highly attenuated in adult macaques, was pathogenic and capable of producing a fatal AIDS-like disease in newborn macaques (Baba et al., 1995 (Baba et al., , 1999 . In contrast, newborn macaques infected with the highly attenuated SIV clone SIVmac1A11, or with Revindependent SIV clones, did not develop the disease (Otsyula et al., 1996; von Gegerfelt et al., 2002) . These observations suggested that virus attenuation observed in adults is not always predictive of pathogenicity in the neonatal host and support the use of neonatal infection as another approach for assessing lentivirus attenuation and pathogenesis. Also, age-related differences in expression of cellular genes known to influence lentivirus replication, such as APOBEC3 family members, are not well characterized and may also influence the outcome of infection with lentiviruses attenuated by loss of accessory gene function. Accordingly, this report describes the inoculation of newborn kittens with a vif-deleted FIV provirus to further examine virus attenuation and pathogenesis associated with the loss of Vif activity. These neonatal infection studies further corroborate the importance of FIV Vif in virus replication and pathogenesis for both neonatal and adult hosts.
Our previous reports showed that inoculation of juvenile cats with a vif-deleted FIV provirus plasmid (FIVpPPRDvif) resulted in an infection detectable only by evidence of virus-specific cellular immune responses and by observation of low FIV Env antibody titres (Gupta et al., 2007; Lockridge et al., 2000) . Reasons for using proviral DNA inoculation for infection of animals with this highly attenuated virus for current studies, included the severe reduction in virus particle infectivity imposed by FIV vif deletion (Lockridge et al., 1999; Paul et al., 2007; Tomonaga et al., 1992) and the possibility of sustained virus production from inoculated proviral plasmid. Furthermore, the lack of feline cell lines shown to be permissive for vif-deleted FIV isolates and the absolute restriction of FIV long terminal repeat-directed provirus expression in non-feline cell lines (Poeschla et al., 1998) provided obstacles towards the production of high titre FIV-pPPRDvif particle inocula for animal infection. Lastly, our earlier studies revealed similar kinetics for induction of viraemia and antiviral antibody upon inoculation of specific-pathogen-free (SPF) juvenile cats with either FIV-pPPR provirus plasmid or with FIV-pPPR particle preparations (Dean et al., 1999; Sparger et al., 1994 Sparger et al., , 1997 . Therefore, proviral DNA inoculation was chosen as the method for infection of newborn SPF kittens to examine further the importance of Vif in virus replication in vivo. The previously described FIVpPPRDvif plasmid that contains the FIV-pPPR molecular clone encoding a 375 bp deletion within the vif gene (Lockridge et al., 1999) , was purified by a commercial kit (EndoFree Plasmid Mega kit; Qiagen) in preparation for inoculation of kittens. All FIV-pPPRDvif and wild type (WT) FIV-pPPR plasmid preparations were tested for virus replication by electroporation of Crandell feline kidney (CRFK) cells (ATCC CCL-94) with plasmid (10 mg) followed by co-cultivation with feline peripheral blood mononuclear cells (PBMC) and assay of PBMC culture supernatants for FIVp24-Gag antigen concentrations as described previously (Gupta et al., 2006) . Transfection of FIV-pPPRDvif plasmid preparations revealed virus production and transient replication of low magnitude compared with replication of WT FIVpPPR in feline PBMC (Fig. 1a) . These observations were consistent with previous studies of the FIV-pPPRDvif provirus plasmid (Gupta et al., 2006; Lockridge et al., 1999) and confirmed the stability of this plasmid.
Eleven kittens were delivered from five pregnant female cats (queens) obtained from the SPF cat colony of the University of California, Davis Feline Nutrition and Pet Care Center. All queens and kittens were housed in pathogen-free quarters of Animal Resources Services (University of California, Davis, USA) and maintained according to regulations and guidelines of the Institutional Animal Care and Use Committee. Within 24 h after birth, one group of five SPF newborn kittens received FIVpPPRDvif provirus plasmid DNA (600 mg) by the intramuscular (i.m.) route (paralumbar muscle) and a second group of three neonatal kittens (positive control group) received an i.m. inoculation with WT FIV-pPPR plasmid DNA (600 mg). A third group of three SPF newborn kittens served as uninfected controls. All inoculated kittens were monitored daily for clinical abnormalities including fever and peripheral lymphadenopathy. Blood sampling was restricted during the first 8 weeks of the study due to size and body weight of the kittens. After 8 weeks into the study, blood samples were collected every 2-6 weeks for haematological, virological and immunological assays. FIVpPPRDvif-inoculated kittens received a second i.m. injection with FIV-pPPRDvif plasmid DNA (300 mg) in the rear limb quadriceps muscle at 42 weeks after primary inoculation and were evaluated for antiviral antibody and virus in peripheral blood for an additional 5 weeks, up to 47 weeks after primary inoculation. Kittens inoculated with WT FIV-pPPR DNA were removed from the study at 36 weeks after inoculation.
PBMC harvested from inoculated kittens were prepared by density-gradient centrifugation in Ficoll-Hypaque (Histopaque; Sigma-Aldrich) and cultivated for virus isolation as described previously (Dean et al., 1999) . After inoculation, virus was isolated from PBMC sampled from all three kittens inoculated with WT FIV-pPPR plasmid at multiple time points, with one WT FIV-pPPR-inoculated kitten testing virus positive as early as 1 week after DNA inoculation (Table 1 ). In contrast, infectious virus could not be recovered from PBMC sampled from any of the five FIVpPPRDvif-inoculated kittens at all time points tested after birth. FIV proviral DNA was also not detected in PBMC preparations sampled from FIV-pPPRDvif-inoculated kittens at either 42 weeks after initial inoculation or 2 weeks after a second FIV-pPPRDvif inoculation (44 weeks after primary inoculation), when assayed by a quantitative realtime TaqMan PCR assay with FIV gag TaqMan probes and primer sequences and protocols described previously (Pedersen et al., 2001) (Table 1) .
No adverse clinical effects were observed for any kitten after plasmid DNA inoculation and no significant differences in Fig. 1 . FIV-pPPRDvif virus replication in vitro and pathogenesis in vivo after inoculation of neonatal kittens. CRFK cells were electroporated with FIV-pPPRDvif (FIV-Dvif ) or WT FIV-pPPR proviral plasmids and co-cultivated with feline PBMC as described previously (Gupta et al., 2006) . Virus production was tested in PBMC culture supernatants with a FIV p24-Gag antigen-capture ELISA (Dandekar et al., 1992) . Data shown for in vitro replication (a) is representative of assays for multiple preparations of FIV-pPPRDvif plasmid. Enumeration of CD4 and CD8 peripheral blood lymphocyte subsets in peripheral blood of kittens inoculated with either FIV-pPPRDvif or WT FIV-pPPR was conducted by flow cytometry analysis as described previously (Barlough et al., 1991) . CD4/CD8 ratios (b) and CD4 T-cell percentages (c) are shown as mean values±SEM for each group. Significant differences between mean values calculated for WT FIV-pPPR-inoculated cats and control cats are denoted by an asterisk (*) and were calculated using the Mann-Whitney test with a confidence interval of 95 % (GraphPad Prism). P values of 0.05 or less were calculated for each time point represented with an asterisk. WT FIV-pPPR-inoculated cats were included in the study up to week 36 after inoculation. FIV-specific T-cell proliferative responses measured in PBMC by a flow cytometric method are shown for each experimental group at 32 weeks (d) and 36 weeks (e) after proviral DNA inoculation. A significant proliferation response was defined as equal to, or greater than, 2-2.5 % FIV-specific proliferating T cells (represented by the dashed cut-off line) and is based on values previously established for uninfected control cats [mean value for SPF cats (n540)+(2¾SD)] (Gupta et al., 2007) . Symbol n indicates data are not available due to loss of sample.
white blood cell, absolute lymphocyte and neutrophil counts were observed between the different experimental and control groups of kittens (data not shown). Peripheral blood CD4/CD8 T-cell ratios and CD4 T-cell percentages (Fig. 1b and c) were comparable between FIV-pPPRDvifinoculated and control kittens, and a normal age-related decline in the CD4/CD8 ratios occurred in both proviral plasmid-inoculated and control groups. However, WT FIVpPPR-inoculated kittens showed significantly lower CD4 Tcell percentages compared with control kittens for multiple time points after inoculation (Fig. 1c) . Significant differences in CD4/CD8 T-cell ratios between WT FIV-pPPRinfected and control kittens were also observed, but only for selected early time points after infection (Fig. 1b) . In contrast, CD8 T-cell percentages were comparable between all three groups with the exception of week 5 after infection, where the mean CD8 T-cell percentage for WT FIV-pPPRinfected kittens was greater than that measured for control kittens (data not shown). Collectively, these findings revealed severely restricted virus replication and absence of pathogenicity for FIV-pPPRDvif infection of neonatal kittens when compared with WT FIV-pPPR, and reproduced observations previously reported for inoculation of juvenile cats with FIV vif mutants (Gupta et al., 2007; Inoshima et al., 1996; Lockridge et al., 2000) . Interestingly, significant changes in CD4/CD8 T-cell ratios and CD4 T-cell percentages have not been reported in juvenile cats infected with the molecular clone FIV-pPPR, a cloned virus previously shown to be relatively non-pathogenic although capable of establishing significant viraemia (Dean et al., 1999; Lockridge et al., 2000; Sparger et al., 1994 Sparger et al., , 1997 . Alterations in the peripheral blood CD4 T-cell population observed for WT FIV-pPPR infection of newborn kittens, further supported the use of neonatal infection studies for examination of pathogenic potential of various WT and mutant FIV isolates. This observation for WT FIV-pPPR neonatal infection contrasts with the lack of pathogenicity exhibited by FIV-pPPRDvif and confirms the absolute attenuation of this FIV vif mutant.
Serum samples collected from kittens after FIV-pPPRDvif inoculation were assayed for antibodies to recombinant FIV p24-Gag by a previously described ELISA (George et al., 1993) . The time point for which antiviral antibody was first detectable could not be determined due to a restriction on blood sampling imposed by the size of the kittens during the first 8 weeks after birth. However, FIV p24-Gag-specific antibody was detected for all WT FIVpPPR-inoculated kittens by 8 weeks after inoculation and ranged in titres from 1 : 10 2 to 1 : 10 5 (Table 2 ). Only one of five FIV-pPPRDvif-inoculated kittens seroconverted, with a low antibody titre of 1 : 10 2 emerging at a later time point (42 weeks after inoculation). The remaining FIVpPPRDvif-inoculated and control kittens were antibody negative with titres less than 1 : 10 2 . Antibody directed against native FIV-pPPR Env was also assayed by using a concanavalin A (Con A) antibody ELISA described previously (Lockridge et al., 2000) and was detected in WT FIV-pPPR-inoculated kittens by 7 weeks after inoculation with titres ranging from 1 : 800 to 1 : 12 800. However, very low FIV Env antibody titres observed for FIV-pPPRDvif-inoculated kittens were comparable to those measured for uninfected control kittens (data not shown). Antiviral antibodies have been reported as either absent or of low titre, and infrequent in published studies characterizing in vivo pathogenesis of vif-deleted lentivirus infections (Desrosiers et al., 1998; Gabuzda et al., 1992; Gupta et al., 2007; Harmache et al., 1996; Inoshima et al., 1996; Kristbjornsdottir et al., 2004; Lockridge et al., 2000) . Emergence of a low FIV Gag antibody titre (1 : 100) for one cat by 42 weeks after FIV-pPPRDvif inoculation, and the subsequent boosting of this antibody titre after a second inoculation (Table 2) , was interesting. This finding suggested persistent expression or virus replication of low magnitude for the inoculated mutant provirus in this particular animal, despite the absence of detectable virus. Overall, the lack of sufficient virus replication to induce a virus-specific antibody response as demonstrated for the remaining four FIV-pPPRDvif-inoculated cats, further attested to the severe attenuation of a vif-deleted FIV isolate that is sustained in vivo upon inoculation of a neonatal host.
Virus-specific cellular immune responses were also assayed in inoculated kittens to investigate further for evidence of FIV-pPPRDvif replication or expression. FIV-specific T-cell proliferative responses were assayed at 32 and 36 weeks after inoculation by using a recently described flow cytometric assay where proliferation is determined by the percentage of PBMC incorporating 5-bromo-29-deoxyuridine after stimulation with inactivated preparations of sucrose-gradient-purified virus preparations of the FIV-PPR biological isolate (Gupta et al., 2007) . Proliferative responses were detected in all five FIV-pPPRDvif-inoculated kittens for at least one of the two time points tested, with three of the five kittens exhibiting responses for both time points (Fig. 1d and e) . Importantly, FIV-specific proliferative responses observed for FIV-pPPRDvif-inoculated kittens were comparable to those measured for WT FIV-pPPR-inoculated kittens. This observation is consistent with previous reports describing evidence of virusspecific T-cell proliferative and cytotoxic responses after inoculation of juvenile and adult SPF cats with FIVpPPRDvif proviral DNA (Gupta et al., 2007; Lockridge et al., 2000) , and implies sustained viral gene expression that is sufficient to produce and maintain cellular immune responses up to 36 weeks after a single inoculation at birth. Additional studies will be required to determine whether persistent provirus plasmid DNA expression or a cellular reservoir of persistent FIV-pPPRDvif virus replication is responsible for these cellular responses, or for the antibody response detected for one FIV-pPPRDvif-inoculated cat.
This study provided the first description of neonatal infection with a vif-deleted lentivirus and further corroborates the severe attenuation conferred on lentivirus replication in vivo by absence of the vif gene product. Given the increased susceptibility of the neonatal host to lentivirus infection and disease, experimental inoculation of newborn animals presented another approach for critical assessment of vif-deleted virus attenuation. The severely restricted virus replication and lack of pathogenicity observed for FIV-pPPRDvif in newborn kittens contrasted with virus replication and pathogenicity shown for WT FIV-pPPR in this study and with the virulence reported for attenuated SIVmac239 nef deletion mutants in newborn macaques. The severity of attenuation and deficiency in cell-free infectivity previously reported for lentivirus vif mutants (Desrosiers et al., 1998; Harmache et al., 1996; Inoshima et al., 1996; Lockridge et al., 2000) , suggested that these mutants might be similarly restricted for virus 2  2  2  2  2  2  2  2  5320  FIVDvif  2  2  2  2  2  2  2  2  5322  FIVDvif  2  2  2  2  2  2  2  2  5326  FIVDvif  2  2  2  2  2  2  2  2  5327  FIVDvif  2  2  2  2  2 5223  Control  2  2  2  2  2  2  2  2  5324  Control  2  2  2  2  2  2  2  2  5325  Control  2  2  2  2  2  2 replication in newborn hosts. This hypothesis is now supported by findings from our current study. Future neonatal infection studies testing vif deletion mutants derived from a pathogenic lentivirus, such as SIVmac239, may be warranted to characterize fully the extent of attenuation imposed by a vif gene mutation.
Persistence of virus-specific cellular immune responses exhibited by cats after FIV-pPPRDvif DNA inoculation was interesting, considering the absence of any detectable viraemia. Similar observations of strong SIV-specific T-cell proliferative responses despite weak antiviral antibody responses were also described for occult SIV and simianhuman immunodeficiency virus infections in rhesus macaques induced by vaginal delivery of low dose virus inoculum (McChesney et al., 1998; Tasca et al., 2007) . Future examination of mechanisms for these persistent cellular responses may be warranted to identify potential FIV-pPPRDvif-permissive cell populations or reservoirs in the host and provide additional insights into Vif interactions with cellular proteins in vivo.
